Segall Bryant & Hamill’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.45M | Sell |
40,463
-132
| -0.3% | -$7.7K | 0.04% | 398 |
|
|
2025
Q4 | $2.19M | Buy |
+40,595
| New | +$1.95M | 0.03% | 423 |
|
|
2023
Q4 | – | Sell |
-78,544
| Closed | -$4.56M | – | 324 |
|
|
2023
Q3 | $4.56M | Sell |
78,544
-1,440
| -2% | -$88.2K | 0.05% | 332 |
|
|
2023
Q2 | $5.11M | Sell |
79,984
-1,785
| -2% | -$120K | 0.05% | 336 |
|
|
2023
Q1 | $5.67M | Sell |
81,769
-700
| -0.8% | -$49.4K | 0.06% | 320 |
|
|
2022
Q4 | $5.93M | Buy |
82,469
+200
| +0.2% | +$15.1K | 0.07% | 292 |
|
|
2022
Q3 | $5.85M | Sell |
82,269
-633
| -0.8% | -$45.9K | 0.07% | 284 |
|
|
2022
Q2 | $6.39M | Buy |
82,902
+2,925
| +4% | +$223K | 0.07% | 274 |
|
|
2022
Q1 | $5.85M | Sell |
79,977
-10,110
| -11% | -$679K | 0.06% | 304 |
|
|
2021
Q4 | $5.62M | Sell |
90,087
-7,817
| -8% | -$459K | 0.05% | 311 |
|
|
2021
Q3 | $5.8M | Buy |
97,904
+18,565
| +23% | +$1.22M | 0.06% | 310 |
|
|
2021
Q2 | $5.3M | Buy |
79,339
+1,210
| +2% | +$78.9K | 0.05% | 317 |
|
|
2021
Q1 | $4.94M | Sell |
78,129
-6,127
| -7% | -$381K | 0.05% | 336 |
|
|
2020
Q4 | $5.23M | Sell |
84,256
-3,432
| -4% | -$211K | 0.06% | 288 |
|
|
2020
Q3 | $5.27M | Buy |
87,688
+665
| +0.8% | +$40K | 0.07% | 254 |
|
|
2020
Q2 | $5.13M | Sell |
87,023
-13,631
| -14% | -$815K | 0.09% | 213 |
|
|
2020
Q1 | $5.61M | Sell |
100,654
-4,703
| -4% | -$287K | 0.11% | 175 |
|
|
2019
Q4 | $6.76M | Buy |
105,357
+10,487
| +11% | +$601K | 0.1% | 196 |
|
|
2019
Q3 | $4.8M | Sell |
94,870
-5,316
| -5% | -$250K | 0.07% | 279 |
|
|
2019
Q2 | $4.55M | Sell |
100,186
-4,613
| -4% | -$215K | 0.07% | 291 |
|
|
2019
Q1 | $5.01M | Sell |
104,799
-3,580
| -3% | -$178K | 0.08% | 266 |
|
|
2018
Q4 | $5.63M | Sell |
108,379
-125
| -0.1% | -$6.72K | 0.1% | 245 |
|
|
2018
Q3 | $6.74M | Sell |
108,504
-11,135
| -9% | -$661K | 0.1% | 251 |
|
|
2018
Q2 | $6.62M | Buy |
119,639
+68,228
| +133% | +$3.68M | 0.1% | 249 |
|
|
2018
Q1 | $3.25M | Buy |
51,411
+639
| +1% | +$41.1K | 0.08% | 255 |
|
|
2017
Q4 | $3.11M | Sell |
50,772
-1,138
| -2% | -$71.2K | 0.07% | 258 |
|
|
2017
Q3 | $3.31M | Buy |
51,910
+880
| +2% | +$51.4K | 0.08% | 256 |
|
|
2017
Q2 | $2.84M | Sell |
51,030
-619
| -1% | -$33.7K | 0.07% | 266 |
|
|
2017
Q1 | $2.81M | Sell |
51,649
-2,941
| -5% | -$161K | 0.07% | 259 |
|
|
2016
Q4 | $3.19M | Buy |
54,590
+781
| +1% | +$42.7K | 0.08% | 244 |
|
|
2016
Q3 | $2.9M | Buy |
53,809
+658
| +1% | +$42.3K | 0.07% | 251 |
|
|
2016
Q2 | $3.91M | Buy |
53,151
+2,800
| +6% | +$198K | 0.1% | 202 |
|
|
2016
Q1 | $3.22M | Buy |
50,351
+2,000
| +4% | +$126K | 0.08% | 256 |
|
|
2015
Q4 | $3.33M | Hold |
48,351
| – | – | 0.08% | 257 |
|
|
2015
Q3 | $2.86M | Buy |
48,351
+100
| +0.2% | +$6.34K | 0.07% | 274 |
|
|
2015
Q2 | $3.21M | Sell |
48,251
-2,029
| -4% | -$134K | 0.07% | 275 |
|
|
2015
Q1 | $3.24M | Hold |
50,280
| – | – | 0.07% | 270 |
|
|
2014
Q4 | $2.97M | Sell |
50,280
-1,500
| -3% | -$84.6K | 0.07% | 279 |
|
|
2014
Q3 | $2.65M | Buy |
51,780
+5,200
| +11% | +$260K | 0.06% | 282 |
|
|
2014
Q2 | $2.26M | Sell |
46,580
-1,476
| -3% | -$72.7K | 0.05% | 245 |
|
|
2014
Q1 | $2.5M | Sell |
48,056
-1,747
| -4% | -$93K | 0.06% | 252 |
|
|
2013
Q4 | $2.65M | Buy |
49,803
+500
| +1% | +$25.5K | 0.06% | 249 |
|
|
2013
Q3 | $2.28M | Buy |
49,303
+9,658
| +24% | +$424K | 0.06% | 258 |
|
|
2013
Q2 | $1.77M | Buy |
+39,645
| New | +$1.72M | 0.05% | 267 |
|
Other funds holding BMY
VCM
VPM
Segall Bryant & Hamill's BMY Position: Q1 2026 in Review
Segall Bryant & Hamill reduced its Bristol-Myers Squibb (BMY) stake by 0.33% in Q1 2026, selling an estimated $7.7K and leaving 40,463 shares worth $2.45M. The position accounts for 0.04% of the portfolio, ranked #398.
Segall Bryant & Hamill first reported a position in BMY in Q2 2013 and has held it in 44 quarters since. The position peaked at $6.76M in Q4 2019. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Segall Bryant & Hamill held 40,463 shares of Bristol-Myers Squibb worth $2.45M as of Q1 2026.
- Segall Bryant & Hamill sold 132 Bristol-Myers Squibb shares in Q1 2026, an estimated $7.7K.
- Bristol-Myers Squibb made up 0.04% of Segall Bryant & Hamill's portfolio in Q1 2026, its #398 holding.
- Segall Bryant & Hamill first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 44 quarters since.
- Segall Bryant & Hamill's Bristol-Myers Squibb position peaked at $6.76M in Q4 2019.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Segall Bryant & Hamill's 13F filing for Q1 2026, filed 15 May 2026.